Hence, NRTKs are vital components of signaling pathways which have the ability to regulate important cellular functions such as apoptosis, survival, proliferation, and cell differentiation.
These non-receptor tyrosine kinase inhibitors bind to catalytic site of a non-receptor tyrosine kinase which prevents phosphorylation and helps to regulate cytostatic activity.
The major classes of tyrosine kinases include Abelson murine leukemia (Abl) and Janus kinases (JAKs) & Src.
In the past few years, non-receptor tyrosine kinase inhibitors (NRTKs) have emerged as one of the most encouraging therapeutics in different types of cancers.
Additionally, these have created large opportunities for the pharma industry to research on variations seen in non-receptor tyrosine kinase inhibitor mechanisms and their precise role for the different types of metabolic and neurodegenerative disorders.A robust clinical pipeline offers a promising situation in terms of future of precise therapeutic response from NRTKs.
Increase in investments in research & development in the pharma & biotech sector has led to development of new innovative compounds, which are showing positive results in clinical trials.